NightHawk Biosciences Inc (NHWK)

[jboatswain]

HS-110 + opdivo poster is not that clear. For instance, we know what immune responders are. 50% OR in IR group is all good. But they are not clear about how many LOW TIL patients have become HIGH TIL? How many from this group have responded.

Currently, I am out of HTBX. I will watch out after a year or so.

A few lessons from HTBX:

(a) Jeff Wolf is a crook. He misled investors in July by saying "we are presented with alternative options instead of dilution". Then did ATM.

(b) HS-410 abstract is totally misleading with 85% and 87% RFS crap.

(c) Corporate presentation is also misleading if we look at P1 data from HS-410 + BCG open arm. They just presented antigen details, but RFS and PFS from 10 patients after a year is not that convincing.

(d) A good lesson for all those who do DD: be conservative when it comes to believing companies documents. Hence, always look for data with large number of patients in P1 or get out before P2 readout or find companies who have passed P2 with large cohorts.

Despite HTBX crookedness, I like their impact and compact platforms, which have a great potential: allogeneic, shared antigen-specific, costimulation.

I will come back once they pass P2 trial in at least one of the indications with flying colors.